| Literature DB >> 32328199 |
Ting Xu1, Pu Guo1, Chao Pi1, Yingmeng He1, Hongru Yang2,3, Yi Hou1, Xianhu Feng1, Qingsheng Jiang4, Yumeng Wei1, Ling Zhao1.
Abstract
Curcumin (CU) has shown broad anti-cancer effects. 5-fluorouracil (5-FU) has been a conventional chemotherapeutic agent for hepatocellular carcinoma. Unfortunately, the nonspecific cytotoxicity and multidrug resistance caused by long-term use limited the clinical efficacy of 5-FU. This study was aimed to investigate whether the combination of CU and 5-FU could generate synergistic effect in inhibiting the human hepatocellular carcinoma. The results of cytotoxicity test showed that compared with applying single drugs, the combination of CU and 5-FU (1:1, 1:2, 1:4, 2:1 and 4:1, mol/mol) presented stronger cytotoxicity in SMMC-7721, Bel-7402, HepG-2 and MHCC97H cells, while the combination groups are relatively insensitive to normal hepatocytes (L02). Among them, the molar ratio of 2:1 combination group showed strong synergistic effect in SMMC-7721cells. Then, western blotting assay further verified that the mechanism of the synergistic effect may be related to the inhibition of the expression of NF-κB (overall) and COX-2 protein. In addition, the synergistic effect was also validated in the xenograft mice in vivo. This research not only provides a novel and effective combination strategy for the therapy of hepatocellular carcinoma but also provides an experimental basis for the development of CU and 5-FU compound preparation. © The author(s).Entities:
Keywords: 5-Fluorouracil; COX-2; Curcumin; Hepatocellular carcinoma cell lines; NF-κB
Year: 2020 PMID: 32328199 PMCID: PMC7171506 DOI: 10.7150/jca.41783
Source DB: PubMed Journal: J Cancer ISSN: 1837-9664 Impact factor: 4.207
Figure 1The IC50 value of each groups of drugs on hepatocarcinoma cells. A: The IC50 value of CU in each group and cell lines. B: The IC50 value of 5-FU in each group and cell lines.
The IC50 values of CU and 5-FU alone and in combination in L02, SMMC-7721, Bel-7402, HepG-2 and MHCC97H cells for 48 h.
| CU/5-FU (mol/mol) | Drugs | IC50 (μmol/L) | ||||
|---|---|---|---|---|---|---|
| L02 | SMMC-7721 | Bel-7402 | HepG-2 | MHCC97H | ||
| 1:01 | CU | 34.08 ± 2.36 | 4.95 ± 1.20 | 19.30 ± 2.29 | 25.00±1.21 | 35.35 ± 2.84 |
| 5-FU | 34.08 ± 2.36 | 4.95 ± 1.20 | 19.30 ± 2.29 | 25.00±1.21 | 35.35 ± 2.84 | |
| 1:02 | CU | 15.06 ± 0.66 | 2.49 ± 0.58 | 16.15 ± 2.01 | 27.34±1.72 | 16.04 ± 1.12 |
| 5-FU | 30.12 ± 1.32 | 4.93 ± 1.17 | 32.3 ± 4.02 | 54.68±3.45 | 32.07 ± 2.25 | |
| 1:04 | CU | 32.1 ± 1.46 | 6.15 ± 1.10 | 7.63 ± 1.31 | 31.07±0.84 | 22.09 ± 1.19 |
| 5-FU | 128.4 ± 5.83 | 24.60 ± 4.40 | 30.52 ± 5.24 | 124.27±3.37 | 88.36 ± 4.77 | |
| 2:01 | CU | 26.45 ± 1.92 | 4.32 ± 2.02 | 45.60 ± 2.56 | 10.36±1.77 | 14.48 ± 1.26 |
| 5-FU | 13.23 ± 0.96 | 2.16 ± 1.05 | 22.80 ± 1.78 | 5.17±0.88 | 7.24 ± 0.63 | |
| 4:01 | CU | 9.33 ± 0.81 | 17.72 ± 4.68 | 17.72 ± 3.88 | 23.59±4.51 | 25.78 ± 2.58 |
| 5-FU | 2.33 ± 0.20 | 4.28 ± 1.17 | 4.43 ± 0.97 | 5.90±1.13 | 6.44 ± 0.64 | |
| - | CU alone | 22.46 ± 2.69 | 89.06 ± 11.85 | 94.74 ± 4.03 | 43.46±5.34 | 65.27 ± 2.22 |
| 5-FU alone | 32.98 ± 1.23 | 21.90 ± 1.54 | 38.48 ± 2.27 | 40.18±6.24 | 43.86 ± 1.99 | |
Figure 2The combination effects (CI) of CU and 5-FU concurrently exposed to the HCC cell lines for 48 h. The CI values were calculated by the method mentioned above. When CI < 1, CI = 1 or CI > 1, it indicates synergism, summation or antagonism effect of the two drugs, respectively.
The CI values of CU and 5-FU alone and in combination in cells for 48 h.
| CU/5-FU (mol/mol) | Cell lines | ||||
|---|---|---|---|---|---|
| L02 | SMMC-7721 | Bel-7402 | HepG-2 | MHCC97H | |
| 1:1 | 2.62 | 0.24004 | 0.60773 | 2.14 | 1.96 |
| 1:2 | 0.78 | 0.15843 | 0.81156 | 0.94 | 1.14 |
| 1:4 | 1.17 | 1.1316 | 0.69721 | 1.48 | 3.04 |
| 2:1 | 3.01 | 0.14698 | 0.43735 | 0.67 | 0.43 |
| 4:1 | 1.6 | 0.36951 | 0.285 | 0.62 | 0.51 |
Figure 3Variety of inhibition rate of combination groups in SMMC-7721 cells with the same concentration of CU (A) or 5-FU (B) after treated with 48 h. Data were expressed as means ± SD (n = 3).
Figure 4Effects of CU and 5-FU alone or in combination on the protein expressions of NF-κB in nucleus, NF-κB in cytoplasm and COX-2 on SMMC-7721 cells by Western blotting analysis. SMMC-7721 cells were treated with CU and 5-FU alone or in combination for 48 h. A: Band 1 was 15 μmol/L of 5-FU; Band 2 was 25 μmol/L of CU; Band 3 was 5 μmol/L of CU + 10 μmol/L of 5-FU; Band 4 was 5 μmol/L of CU + 5 μmol/L of 5-FU; Band 5 was 5 μmol/L of CU + 2.5 μmol/L of 5-FU; Band 6 was 10 μmol/L of CU + 5 μmol/L of 5-FU; Band 7 was 2.5 μmol/L of CU + 5 μmol/L of 5-FU; Band 8 was blank group. B: NF-κB and COX-2 protein expression in low- and high-concentration groups. The results are representative of at least three independent experiments run in triplicate and expressed as the means ± SEM. *P > 0.05 vs. the 5-FU group; P < 0.05 vs. groups among groups. *, p < 0.05, **, p < 0.01, and ***, p < 0.001, compared to the blank group; △, p < 0.05, △△, p < 0.01, and △△△, p < 0.001, compared to the 5-FU alone group; ▲, p < 0.05, ▲▲, p < 0.01, and ▲▲▲, p < 0.001, compared to the CU alone group.
Figure 5Antitumor efficacy and toxicity of CU and 5-FU alone or in combination in nude mice bearing SMMC-7721 tumor xenografts in vivo. A: The changes of body weight (g) before and after treated with CU and 5-FU alone or in combination in nude mice; B: The changes of tumor volume with different groups in nude mice; C: Tumor weight (g) of 7721-bearing nude mice treated with CU and 5-FU alone or in combination on day 31st when the mice were humanely sacrificed (mean ± SD). Note: T-test, △P < 0.05 vs. the control negative group; #P < 0.05 vs. the 5-FU group; D: Tumor inhibitory rates (%) of 7721-bearing nude mice treated with 5-FU and CU alone or in combination on day 31st.